S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

• Petra Langerbeins,
• Sandra Robrecht,
• Pascal Nieper,
• Paula Cramer,
• Moritz Fürstenau,
• Othman Al-Sawaf,
• Anna-Maria Fink,
• Karl-Anton Kreuzer,
• Ursula Vehling-Kaiser,
• Eugen Tausch,
• Christof Schneider,
• Lothar Müller,
• Michael Eckart,
• Rudolf Schlag,
• Werner Freier,
• Tobias Gaska,
• Christina Balser,
• Marcel Reiser,
• Martina Stauch,
• Clemens Wendtner,
• Kirsten Fischer,
• Stephan Stilgenbauer,
• Barbara Eichhorst,
• Michael Hallek

Affiliations

Petra Langerbeins

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Sandra Robrecht

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Pascal Nieper

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Paula Cramer

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Moritz Fürstenau

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Othman Al-Sawaf

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Anna-Maria Fink

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Karl-Anton Kreuzer

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Ursula Vehling-Kaiser

2 Outpatient Clinic, Outpatient Clinic, Landshut, Germany

Eugen Tausch

3 University of Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Christof Schneider

3 University of Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Lothar Müller

4 Onkologie Unter Ems, Onkologie Unter Ems, Leer, Germany

Michael Eckart

5 Practice for Oncology and Hematology, Practice for Oncology and Hematology, Erlangen, Germany

Rudolf Schlag

6 Practice for Oncology and Hematology, Practice for Oncology and Hematology, Wuerzburg, Germany

Werner Freier

7 Medicinum, Practice for Oncology and Hematology, Hildesheim, Germany

Tobias Gaska

8 Brüderkrankenhaus St. Josef, Department of Hematology and Oncology, Paderborn, Germany

Christina Balser

9 Practice for Oncology and Hematology, Practice for Oncology and Hematology, Marburg, Germany

Marcel Reiser

10 Practice for Oncology and Hematology, Practice for Oncology and Hematology, Cologne, Germany

Martina Stauch

11 Practice for Oncology and Hematology, Practice for Oncology and Hematology, Kronach, Germany

Clemens Wendtner

12 Klinikum Schwabing, Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich, Germany

Kirsten Fischer

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Stephan Stilgenbauer

3 University of Ulm, Division of CLL, Department of Internal Medicine III, Ulm, Germany

Barbara Eichhorst

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany

Michael Hallek

1 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, Cologne, Germany